Multicenter, Prospective Trial of Nonendoscopic Biomarker-Driven Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.

Overview of attention for article published in American Journal of Gastroenterology, May 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 9 news stories from 9 outlets.

NEW YORK - Lucid (NASDAQ:LCID) Diagnostics Inc. (NASDAQ:LUCD), a medical diagnostics company specializing in cancer prevention…

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early…

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early…

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 5 additional news stories.